The EndoPredict test is an RNA-based reverse transcription PCR assay that predicts the likelihood of disease recurrence in women with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2−) breast cancer [1]. This evidence concerns the gene ERBB2 and breast carcinoma.